Valeritas Holdings, Inc. (VLRX)

6.68
NASDAQ
Prev Close 6.87
Day Low/High 6.68 / 7.20
52 Wk Low/High 5.20 / 52.00
Exchange NASDAQ
Shares Outstanding 6.89B
Market Cap 47.33M
Div & Yield N.A. (N.A)

Latest News

Valeritas Reports Fourth Quarter And Full Year 2016 Financial Results

Valeritas Reports Fourth Quarter And Full Year 2016 Financial Results

Conference Call and Webcast Today, February 21, at 10 a.m. EST

Valeritas Presents Data Showing Greater Reductions In A1c And Insulin Dose With V-Go® Wearable Insulin Delivery Device Compared To Insulin Pen Devices In Patients With Type 2 Diabetes

Valeritas Presents Data Showing Greater Reductions In A1c And Insulin Dose With V-Go® Wearable Insulin Delivery Device Compared To Insulin Pen Devices In Patients With Type 2 Diabetes

Data presented at The 10th International Conference on Advanced Technologies & Treatments for Diabetes

Valeritas Promotes Matthew Nguyen To Chief Commercial Officer

Valeritas Promotes Matthew Nguyen To Chief Commercial Officer

Responsible for continued growth of V-Go® Insulin Delivery device for patients with type 2 diabetes

V-Go® Data And Clinical Benefit Discussed During Panel Presentation On Insulin Therapy And Delivery At AADE 2016

V-Go® Data And Clinical Benefit Discussed During Panel Presentation On Insulin Therapy And Delivery At AADE 2016

Valeritas Demonstrates Ease of Use of V-Go Disposable Insulin Delivery Device to Attending Clinicians

Valeritas Announces Positive Results In Four Studies On V-Go® Disposable Insulin Delivery Device At ADA 2016

Valeritas Announces Positive Results In Four Studies On V-Go® Disposable Insulin Delivery Device At ADA 2016

Studies Demonstrate Clinical and Cost Benefit of V-Go

Valeritas Announces Retrospective Analysis Of The V-Go® Disposable Insulin Delivery Device Published Online In Drugs-Real World Outcomes, An International, Peer-Reviewed Journal

Valeritas Announces Retrospective Analysis Of The V-Go® Disposable Insulin Delivery Device Published Online In Drugs-Real World Outcomes, An International, Peer-Reviewed Journal

Data show that switching to V-Go for insulin delivery in a poorly controlled diabetes population at high risk results in significant glycemic improvement and payer cost savings